20.59
-0.51 (-2.42%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Tyra Biosciences, Inc. | Bearish | Bullish |
Stockmoo Score
|
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company’s in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Canaan Partners Xi Llc | 30 Jun 2024 | 4,409,991 |
| Sio Capital Management, Llc | 30 Jun 2024 | 600,294 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 33.00 (Piper Sandler, 60.27%) | Buy |
| Median | 26.50 (28.70%) | |
| Low | 23.00 (HC Wainwright & Co., 11.71%) | Buy |
| Average | 27.25 (32.35%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 19.91 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 15 Aug 2024 | 33.00 (60.27%) | Buy | 22.00 |
| Oppenheimer | 08 Aug 2024 | 25.00 (21.42%) | Buy | 20.34 |
| 03 Jul 2024 | 28.00 (35.99%) | Buy | 16.97 | |
| Wedbush | 08 Aug 2024 | 28.00 (35.99%) | Buy | 20.34 |
| 03 Jul 2024 | 28.00 (35.99%) | Buy | 16.97 | |
| HC Wainwright & Co. | 03 Jul 2024 | 23.00 (11.70%) | Buy | 16.97 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Sep 2024 | Announcement | Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference |
| 10 Sep 2024 | Announcement | Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer |
| 07 Aug 2024 | Announcement | Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights |
| 02 Jul 2024 | Announcement | Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |